Gilead stock falls after disappointing lung cancer study results

Gilead will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug, known as Trodelvy.

Previous post FTX’s Alameda Research drops lawsuit against Grayscale
Next post Spirit Airlines shares extend rebound after it appeals ruling blocking JetBlue merger